
REPUBLIC OF LEBANON MINISTRY OF PUBLIC HEALTH Lebanon Clinical Trials Registry

Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell Disease

23/08/2025 06:35:17

Protocol number GBT440-007 Study registered at the country of origin: Specify
Study registered at the country of origin: Specify
Study registered at the country of origin: Specify
Study registered at the country of origin: Specify
Type of registration: Justify
Requested by Sponsor- Registry not in place upon study initiation
Primary sponsor: Country of origin
United States of America
Date of registration in national regulatory agency
11/06/2014
Acronym
Acronym



REPUBLIC OF LEBANON MINISTRY OF PUBLIC HEALTH Lebanon Clinical Trials Registry

Interventions: Specify

Drug: GBT440 administered as oral capsules, tablets, dispersible tablets or powder for oral suspension.

Key inclusion and exclusion criteria: Inclusion criteria

1. Male or female participants with homozygous hemoglobin SS (HbSS) or hemoglobin S beta0 thalassemia (HbS β0 thal). 2. Age:

• Part A - 6 to 17 years of age (Cohort 1 [12 to 17] and Cohort 2 [6 to 11] as defined in the Study Design)

Part B – 12 to 17 years of age

Part C – 4 to 17 years of age

• Part D – 6 months to < 4 years of age

3. Hydroxyurea (HU) therapy:

• Parts A, B, and C – A participant taking HU may be enrolled if the dose has been stable for at least 3 months with no anticipated need for dose adjustments during the study and no sign of hematological toxicity.

• Part D – A participant taking HU may be enrolled if the dose has been stable for at least 1 month. Titration to the maximum tolerated dose (MTD) is allowed during the study.

4. Hemoglobin (Hb):

Part A – No restriction

• Part B – Hb ≤ 10.5 g/dL

• Part C – Hb ≤ 10.5 g/dL

• Part D – Hb ≤ 10.5 g/dL

5. Written informed parental/guardian consent and participant assent has been obtained per institutional review board (IRB)/Ethics Committee (EC) policy and requirements, consistent with ICH guidelines.

6. Participants in Part B (only) of the study must complete a minimum of 14 days with ePRO to be enrolled. Investigator discretion will be used to determine if a participant who has previously been screen failed due to a lack of baseline ePRO data collection can be invited back for rescreening.

7. If sexually active and female, must agree to abstain from sexual intercourse or to use a highly effective method of contraception throughout the study period and for 30 days after discontinuation of study drug. If sexually active and male, must agree to abstain from sexual intercourse or willing to use barrier methods of contraception throughout the study period and for 30 days after discontinuation of study drug.

8. Females of child-bearing potential are required to have a negative pregnancy test before the administration of study drug.

9. Sufficient venous access to permit collection of PK samples and monitoring of laboratory safety variables, in the opinion of the Investigator. 10. For Part C only, participants 12 to 17 years of age must have a TCD velocity ≥ 140 cm/sec by nonimaging TCD or ≥ 125 cm/sec by TCDi measured anytime during screening.

Key inclusion and exclusion criteria: Specify gender

Both	
Key inclusion and exclusion criteria: Age minimum	Key inclusion and exclusion criteria: Age maximum
0	17

Key inclusion and exclusion criteria: Exclusion criteria

Key inclusion and exclusion criteria: Gender

1. Any one of the following requiring medical attention within 14 days prior to signing the informed consent form (ICF):

Vaso-occlusive crisis (VOC)

Acute chest syndrome (ACS)

Splenic sequestration crisis

Dactylitis

2. Requires chronic transfusion therapy.

3. History of stroke or meeting criteria for primary stroke prophylaxis (history of two TCD measurements ≥ 200 cm/sec by nonimaging TCD or ≥ 185 cm/sec by TCDi).

• For the potential modification, addition of approximately 20 participants enrolled in Part C, TCD ≥ 170 cm/sec by nonimaging TCD or ≥ 155 cm/sec by TCDi.

4. Transfusion within 30 days prior to signing the ICF.

5. Renal dysfunction requiring chronic dialysis or creatinine ≥ 1.5 mg/dL.

6. Hepatic dysfunction characterized by alanine aminotransferase (ÅLT) > 4× upper limit of normal (ULN) for age.

7. Clinically relevant cardiac abnormality, in the opinion of the Investigator, such as:

Hemodynamically significant heart disease, eg, congenital heart defect, uncompensated heart failure, or any unstable cardiac condition
An arrhythmic heart condition requiring medical therapy

8. QTcF > 450 msec, congenital long QT syndrome, second or third degree heart block at rest (with the exception of asymptomatic Mobitz type I second degree heart block).

9. Received an investigational drug within 30 days or 5 half-lives, whichever is longer, of signing the ICF.

10. Heavy smoker (defined as smoking more than 10 cigarettes/day or its nicotine equivalent including e-cigarettes).

11. Unlikely to comply with the study procedures.

12. Other medical, psychological, or addictive condition that, in the opinion of the Investigator, would confound or interfere with evaluation of

safety and/or PK of the investigational drug, prevent compliance with the study protocol, or preclude informed consent.

Participants who do not have a TCD window (Part B and C only) (ie, participants who are unable to have a TCD due to skull ossification).
 For Part C only, prior participation in Part B.

15. Active symptomatic COVID-19 infection.

In addition, for Part D only:

16. Body weight < 5 kg for 1 month prior to the screening visit and at the screening visit.

17. Any condition affecting drug absorption, such as major surgery involving the stomach or small intestine (prior cholecystectomy is acceptable).

18. History of malignancy within the past 2 years prior to treatment Day 1 requiring chemotherapy and/or radiation (with the exception of local therapy for non-melanoma skin malignancy).

REPUBLIC OF LEBANON Lebanon Clinical Trials Registry

19. Clinically significant bacterial, fungal, parasitic, or viral infection currently receiving or that will require therapy.

• Participants with acute bacterial infection requiring antibiotic use should delay screening until the course of antibiotic therapy has been completed and the infection has resolved, in the opinion of the investigator.

• Known active hepatitis A, B, or C infection or human immunodeficiency virus (HIV)-positive.

MINISTRY OF PUBLIC HEALTH

• Known active malaria.

Type of study

Interventional

Type of intervention	Type of intervention: Specify	type
Pharmaceutical	N/A	
Trial scope	Trial scope: Specify scope	
Therapy	N/A	
Study design: Allocation	Study design: Masking	
N/A: Single arm study	Open (masking not used)	
Study design: Control	Study phase	
Dose comparison	2	
Study design: Purpose	Study design: Specify purpos	e
Treatment	N/A	
Study design: Assignment	Study design: Specify assign	ment
Single	N/A	
IMP has market authorization	IMP has market authorization	: Specify
Yes, Worldwide	USA, UAE, EU, GB, Oman and	
Name of IMP	Year of authorization	Month of authorization
OXBRYTA	2019	11
Type of IMP		
Others		
Pharmaceutical class		
Allosteric modulator of hemoglobin-oxygen affinity		
Therapeutic indication Sickle Cell Disease		

Therapeutic benefit

Voxelotor is an orally bioavailable HbS polymerization inhibitor that binds specifically to HbS with a 1:1 stoichiometry, and exhibits preferential partitioning to RBCs. By increasing Hb's affinity for oxygen, voxelotor inhibits HbS polymerization in a dose dependent manner that may improve deformability, decrease the viscosity of SCD blood, and ultimately increase blood flow in the microcirculation, thus improving net O2 delivery. Therefore, chronically modifying 20% to 30% of HbS with voxelotor in subjects with SCD is expected to deliver the clinical benefits of reducing HbS polymerization while improving O2 delivery to peripheral tissues.

Study mode	
------------	--

N/A

Study model: Explain model N/A

Study model: Specify model

N/A

 \sim

REPUBLIC OF LEBANON Lebanon Clinical Trials Registry

Time perspective N/A Time perspective: Specify perspective N/A	Time perspective: Explain time perspective N/A
Target follow-up duration	Target follow-up duration: Unit
Number of groups/cohorts	
Biospecimen retention None retained	Biospecimen description N/A
Target sample size 24	Actual enrollment target size
Date of first enrollment: Type Actual	Date of first enrollment: Date 21/07/2016
Date of study closure: Type Actual	Date of study closure: Date 29/12/2023
Recruitment status Recruiting	Recruitment status: Specify
Date of completion	
IPD sharing statement plan No	IPD sharing statement description N/A
Additional data URL https://clinicaltrials.gov/ct2/show/NCT02850406 Admin comments	

Bir Hassan, Jnah, next to Ogero Beirut- Lebanon clinicaltrials@moph.gov.lb

Trial status Approved



Secondary Identifying Numbers Full name of issuing authority Secondary identifying number Clinicaltrials.gov NCT02850406 EU Clinical Trials Registry EudraCT: 2016-004209-15

Sources of Monetary or Material Support

Name

Global Blood Therapeutics, Inc. USA

Secondary Sponsors

No Sponsors

Contac	Contact for Public/Scientific Queries					
Contact type	Contact full name	Address	Country	Telephone	Email	Affiliation
Public	Dr. Adlette Inati	Tripoli	Lebanon	961322803 3	adlette.inati@lau. edu.lb	Nini Hospital
Scientific	Mark Davis	181 Oyster Point Blvd., South San Francisco, CA 94080	United States of America	(925) 336- 1055	mdavis@gbt.com	Global Blood Therapeuti cs
Public	Dr. Miguel Abboud	Beirut	Lebanon	961135000 0	ma56@aub.edu.l b	American University of Beirut Medical Center

Centers/Hospitals Involved in the Study			
Center/Hospital name	Name of principles investigator	Principles investigator speciality	Ethical approval
American University of Beirut Medical Center	Dr. Miguel Abboud	Pediatric Hematology- Oncology	Approved
Rafik Hariri University Hospital	Dr. Adlette Inati	Pediatric Hematology- Oncology	Approved
Nini Hospital	Dr. Adlette Inati	Pediatric Hematology- Oncology	Approved





Ethics Review				
Ethics approval obtained	Approval date	Contact name	Contact email	Contact phone
American University of Beirut Medical Center	09/07/2018	Dr. Fuad Ziyadeh	irb@aub.edu.lb	9611738025
Rafic Hariri University Hospital	31/08/2018	Dr. lyad Issa	NA	9611830000
Nini Hospital	31/08/2018	Dr. Nabil Kabbara	NA	9616431400

Countries of Recruitment Name Lebanon United States of America United Kingdom

Health Conditions or Problems Studied			
Condition Code Keyword			
Sickle Cell Disease	Sickle-cell disorders (D57)	Sickle Cell, Anemia, Hemolytic, Congenital, Hematologic Diseases	


Interventions		
Intervention	Description	Keyword
Drug	GBT440	Oral Capsule, Tablet, Dispersible Tablet or Powder for Oral Suspension





Primary Outcomes		
Name	Time Points	Measure
Part A: Pharmacokinetic profile of GBT440 including maximum concentration	Pre-dose to Day 15	Pharmacokinetic profile
Part A: Pharmacokinetic profile of GBT440 including the time taken to reach the maximum concentration	Pre-dose to Day 15	Pharmacokinetic profile
Part A: Pharmacokinetic profile of GBT440 including the total drug concentration over time	Pre-dose to Day 15	Pharmacokinetic profile
Part B: Change in hemoglobin	Baseline to Week 24	Hemoglobin in Blood
Part C: Change in cerebral blood flow	Baseline to Week 48	TAMM TCD velocity
Part D	During Study Duration	Incidence of TEAEs and SAEs

Key Secondary Outcomes		
Name	Time Points	Measure
Part A: Number of participants with treatment-related adverse events	Days 1 - 15	Assessed by CTCAE v4.03
Part B: Multiple Dose effect on Clinical Measures of Hemolysis	Day 1 - Week 24	Clinical Measures of Hemolysis
Part B: Pharmacokinetic profile of GBT440 including maximum concentration	Pre-dose to Week 24	Pharmacokinetic profile
Part B: Pharmacokinetic profile of GBT440 including the time taken to reach the maximum concentration	Pre-dose to Week 24	Pharmacokinetic profile
Part B: Pharmacokinetic profile of GBT440 including the total drug concentration over time	Pre-dose to Week 24	Pharmacokinetic profile
Part C: Multiple dose effect on clinical measures of hemolysis	Baseline to Week 24 and Week 48	Clinical Measures of Hemolysis
Part C: Change in cerebral blood flow	Baseline to Week 24	Measured by the TAMM TCD velocity
Part C: Pharmacokinetic profile of GBT440 including maximum concentration	Pre-Dose to Week 48	Pharmacokinetic profile
Part C: Pharmacokinetic profile of GBT440 including the time taken to reach the maximum concentration	Pre-Dose to Week 48	Pharmacokinetic profile
Part C: Pharmacokinetic profile of GBT440 including the total drug concentration over time	Pre-Dose to Week 48	Pharmacokinetic profile
Part D: Whole blood and plasma voxelotor PK (Cmax, AUC, t1/2, if appropriate) and occupancy	Baseline to Week 24 and Week 48	Change in Hb, LDH, indirect bilirubin, and reticulocyte count
Part D: Whole blood and plasma voxelotor PK (Cmax, AUC, t1/2, if appropriate) and occupancy	-	Time to initial Hb response, defined as change from baseline in Hb > 1g/dL
Part D: Whole blood and plasma voxelotor PK (Cmax, AUC, t1/2, if appropriate) and occupancy	During whole study duration	Incidence of stroke and VOC





Trial Results Summary results Study results globally Date of posting of results summaries Date of first journal publication of results Results URL link Baseline characteristics Participant flow Adverse events Outcome measures URL to protocol files